A Phase II Study of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients with Previously Untreated Indolent non-Hodgkin’s Lymphoma

Bortezomib-containing combinations are active in non-Hodgkin lymphoma (NHL) although peripheral neuropathy can limit its dose intensity. Based on our phase I findings, we conducted a phase II trial of bortezomib in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, predn...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Cohen, Jonathon B., Switchenko, Jeffrey M., Koff, Jean L., Sinha, Rajni, Kaufman, Jonathan L., Khoury, H. Jean, Bumpers, Nassoma, Colbert, Amanda, Hutchison-Rzepka, Amanda, Nastoupil, Loretta J., Heffner, Leonard T., Langston, Amelia, Lechowicz, Mary Jo, Lonial, Sagar, Flowers, Christopher R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4626332/
https://ncbi.nlm.nih.gov/pubmed/26248505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13637
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados